From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

Shuhong Zhang, Sherif Farag

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects. Areas covered: In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM. Expert opinion: There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.

Original languageEnglish
Pages (from-to)1015-1028
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Multiple Myeloma
Cell Biology
Therapeutics
ENMD 2076
Expert Testimony
Drug Discovery
Molecular Biology
Phosphotransferases
Biomarkers
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • apoptosis
  • aurora kinase inhibitor
  • multiple myeloma
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

From cell biology to therapy : ENMD-2076 in the treatment of multiple myeloma. / Zhang, Shuhong; Farag, Sherif.

In: Expert Opinion on Investigational Drugs, Vol. 20, No. 7, 07.2011, p. 1015-1028.

Research output: Contribution to journalArticle

@article{94d57f0382a7482d9ece44ee0e8f2856,
title = "From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma",
abstract = "Introduction: Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects. Areas covered: In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM. Expert opinion: There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.",
keywords = "apoptosis, aurora kinase inhibitor, multiple myeloma, tyrosine kinase inhibitor",
author = "Shuhong Zhang and Sherif Farag",
year = "2011",
month = "7",
doi = "10.1517/13543784.2011.584869",
language = "English",
volume = "20",
pages = "1015--1028",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - From cell biology to therapy

T2 - ENMD-2076 in the treatment of multiple myeloma

AU - Zhang, Shuhong

AU - Farag, Sherif

PY - 2011/7

Y1 - 2011/7

N2 - Introduction: Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects. Areas covered: In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM. Expert opinion: There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.

AB - Introduction: Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects. Areas covered: In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM. Expert opinion: There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.

KW - apoptosis

KW - aurora kinase inhibitor

KW - multiple myeloma

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79958817256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958817256&partnerID=8YFLogxK

U2 - 10.1517/13543784.2011.584869

DO - 10.1517/13543784.2011.584869

M3 - Article

C2 - 21615212

AN - SCOPUS:79958817256

VL - 20

SP - 1015

EP - 1028

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 7

ER -